{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Time to death was defined as the time from the date of enrollment to the date of death. Participants who dropped out or completed the study were considered censored observations. Time to death was assessed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \\<50 nmol/mmol creatinine).","id":"OG000","title":"Zoledronic Acid Every 12 Weeks"},{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \\<50 nmol/mmol creatinine, respectively).","id":"OG001","title":"Zoledronic Acid Every 4 Weeks or 12 Weeks"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all participants who were enrolled in this study.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Time to Death","type":"SECONDARY","unitOfMeasure":"years"}